C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring
C-mo Medical Solutions is a pioneering Digital Health start-up that is unlocking the power of cough monitoring. The company has now secured additional funding from Novalis Biotech to advance its mission of revolutionising cough assessment and disease management.
Founding team of C-mo Medical Solutions. From left to right: Filipe Valadas, Alexandra Lopes, Diogo Tecelão, Sara Lobo and Miguel Andrade.
C-mo Medical Solutions has announced an extension to its seed investment round. The round now totals €4.8 million and with the addition of Novalis Biotech as a new investor. Novalis is joining the seed investment round led by Boehringer Ingelheim Venture Fund and participation from Portugal Ventures and High-Tech Gründerfonds (HTGF).
C-mo Medical Solutions is committed to solving the pressing need to better assess chronic cough, a symptom that affects more than 700 million adults worldwide.
Diogo Tecelão, co-founder and CEO of the company, emphasises: “Cough is a clinically rich symptom that holds valuable information about the patient’s health. However, the lack of tools to assess and manage chronic cough remains a major unmet medical need. Our mission is to change that!”
C-mo’s innovative product suite is unlocking the full potential of cough assessment.
Diogo Tecelão highlights: “Our unique technology analyses the subtle characteristics of the patient’s cough, translating them into actionable insights that add significant value in key several usecases. C-mo has the potential to greatly speed-up diagnosis, optimise treatment courses, improve disease management, and support pharmaceutical research”.
Kjell Mortier, Fund Manager at Novalis Biotech notes: "We are very happy to support C-mo and join the investor consortium. We are impressed by the complementarity and dedication of the C-mo team that developed this innovative product. Translation of a clinically relevant symptom as cough into an objective, measurable marker is currently missing in drug development or treatment. We are convinced C-mo’s technology can help to better assess and treat underlying conditions, thereby helping patients to get access to the right treatment.”
Diogo Tecelão concludes: “We are thrilled to welcome Novalis Biotech as a new investor, as their experience in healthcare will bring great added value to our company”. This extension of the seed investment round will allow the company to further explore and unlock the full potential of cough assessment, namely by expanding the capabilities and applications of their technology.
About C-mo Medical Solutions
C-mo Medical Solutions is an award-winning Digital Health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential of cough assessment and solve the major unmet medical needs associated with the management of chronic cough. Find out more at www.c-mo.solutions.
About Novalis Biotech
Novalis Biotech (Ghent, Belgium) is an early-stage venture capital investor in technologies that revolutionise healthcare. The company’s core competence lies in digitalization in the life sciences with a focus on capital-light “enabling technologies” such as bioinformatics, AI, genomics, personalised medicine, research or manufacturing tools, and diagnostics. For more information, please visit www.noval.is.